Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced Metastatic NSCLC”

724 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 724 results

Not applicableLooking for participantsNCT07096258
What this trial is testing

EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
Hedera Dx SA 1,000
Early research (Phase 1)Looking for participantsNCT07182149
What this trial is testing

NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Who this might be right for
HNSCCESCCEsophageal Adenocarcinoma+7 more
Normunity AccelCo, Inc. 150
Testing effectiveness (Phase 2)Looking for participantsNCT06567015
What this trial is testing

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Pierre Fabre Medicament 171
Testing effectiveness (Phase 2)Study completedNCT00890825
What this trial is testing

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 88
Large-scale testing (Phase 3)Looking for participantsNCT06881784
What this trial is testing

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLC+2 more
Revolution Medicines, Inc. 590
Large-scale testing (Phase 3)Study completedNCT00931008
What this trial is testing

Study to Evaluate SID 530 Compared to Taxotere

Who this might be right for
Non-Small Cell Lung Cancer
SK Chemicals Co., Ltd. 42
Testing effectiveness (Phase 2)Study completedNCT00615758
What this trial is testing

Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV

Who this might be right for
Non Small Cell Lung Cancer
Hellenic Oncology Research Group 50
Testing effectiveness (Phase 2)Study completedNCT00425191
What this trial is testing

Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.

Who this might be right for
Non-small Cell Lung Cancer
Sanofi 165
Very early researchEnded earlyNCT03454243
What this trial is testing

Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced or Metastatic Solid Tumors
Hoffmann-La Roche 1
Early research (Phase 1)Study completedNCT03150810
What this trial is testing

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors
BeiGene 139
Testing effectiveness (Phase 2)Looking for participantsNCT06868485
What this trial is testing

Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Wayshine Biopharm, Inc. 40
Testing effectiveness (Phase 2)Study completedNCT02031458
What this trial is testing

Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 667
Testing effectiveness (Phase 2)Study completedNCT00085813
What this trial is testing

Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Cancer
GlaxoSmithKline 70
Large-scale testing (Phase 3)Active Not RecruitingNCT04765059
What this trial is testing

Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 98
Testing effectiveness (Phase 2)Ended earlyNCT00359450
What this trial is testing

Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)

Who this might be right for
Non-small Cell Lung Cancer
Bristol-Myers Squibb 186
Not applicableUnknownNCT02904850
What this trial is testing

Validation of a Kinetic Model of Erlotinib

Who this might be right for
Lung Cancer
University Hospital, Strasbourg, France 50
Large-scale testing (Phase 3)Active Not RecruitingNCT05132075
What this trial is testing

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 95
Large-scale testing (Phase 3)Looking for participantsNCT07185997
What this trial is testing

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Who this might be right for
Non-Small-Cell Lung CancerMetastatic Non-Small-Cell Lung CancerAdvanced Non-Small-Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.
Large-scale testing (Phase 3)Active Not RecruitingNCT06396065
What this trial is testing

Phase III Study of AK112 for NSCLC Patients

Who this might be right for
Non-Squamous Non-small Cell Lung Cancer
Summit Therapeutics 420
Early research (Phase 1)Ended earlyNCT00955942
What this trial is testing

Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy

Who this might be right for
Lung CancerRadiation Toxicity
Abramson Cancer Center at Penn Medicine 48
Next Page
480